Thrombolysis induces cerebral hemorrhage in a mouse model of cerebral amyloid angiopathy.
We studied the impact of cerebral amyloid angiopathy on tissue plasminogen activator-induced cerebral hemorrhages in APP23 transgenic mice. Results show that the intravenous administration of tissue plasminogen activator in APP23 mice leads to an increase in cerebral amyloid angiopathy-associated microhemorrhages and can provoke parenchymal and subarachnoidal hematomas. We conclude that cerebral amyloid angiopathy is a risk factor for cerebral hemorrhage caused by tissue plasminogen activator administration in mice and stress the need for more comprehensive studies of the relation between cerebral amyloid angiopathy and tissue plasminogen activator-induced cerebral hemorrhages in elderly and Alzheimer's disease patients.
Department of Neuropathology, Institute of Pathology, University Hospital Basel, Schönbeinstrasse 40, CH-4003 Basel, Switzerland.
David T
DT
Winkler
Luc
L
Biedermann
Markus
M
Tolnay
Peter R
PR
Allegrini
Matthias
M
Staufenbiel
Christoph
C
Wiessner
Mathias
M
Jucker
D000818:Animals; D016657:Cerebral Amyloid Angiopathy / Q000503:physiopathology*; D002540:Cerebral Cortex / Q000187:drug effects* / Q000473:pathology; D002543:Cerebral Hemorrhage / Q000209:etiology*; D000075202:Contraindications; D004195:Disease Models, Animal; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D008875:Middle Aged; D015912:Thrombolytic Therapy / Q000009:adverse effects*; D010959:Tissue Plasminogen Activator / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator